Clinical trial
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee
NCT04120402 is registered in ClinicalTrials.gov with Eupraxia Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee
- Lead sponsor
- Eupraxia Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 10, 2021
- Completion date
- June 1, 2023
- Enrollment
- 318 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.